来源：视频滚动新闻 11月7日，港股通医药ETF（513200）跌1.97%，成交额1.91亿元。当日份额增加400.00万份，最新份额 为18.13亿份，近20个交易日份额增加3800.00万份。最新资产净值计算值为20.57亿元。港股通医药ETF （513200）业绩比较基准为中证港股通医药卫生综合指数收益率(使用估值汇率折算)，管理人为易方达 基金管理有限公司，基金经理为伍臣东，成立（2022-01-19）以来回报为13.45%，近一个月回报 为-13.15%。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息 （包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个 人投资建议。 ...

Core Viewpoint - The pharmaceutical and healthcare indices in the Chinese stock market have shown positive performance, with significant inflows into innovative drug ETFs, indicating a growing interest in the sector [1][2]. Group 1: Index Performance - The CSI 300 Pharmaceutical and Healthcare Index increased by 1.2% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index rose by 1.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Biotechnology Theme Index both saw a rise of 0.7% [1]. - The CSI Innovative Drug Industry Index experienced a slight increase of 0.01% [1]. Group 2: ETF Activity - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of 11 million units in the first half of the day, bringing its total size to over 1.5 billion yuan, a historical high [1]. - The index tracked by the Hang Seng Innovative Drug ETF focuses on leading innovative drug companies in the Hong Kong stock market, comprising no more than 40 stocks involved in innovative drug research, development, and production [2]. - The rolling price-to-earnings ratio for the Hang Seng Innovative Drug Index is currently at 56.2 times [2]. Group 3: Valuation Metrics - The rolling price-to-earnings ratio for the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index stands at 30.4 times, with a valuation percentile of 48.1% since 2017 [2]. - The rolling price-to-earnings ratio for the CSI Innovative Drug Industry Index is not specified, but it focuses on A-share innovative drug leaders, comprising no more than 50 stocks involved in innovative drug research and development [2].